Soligenix Inc (SNGX)

[236T568]

This pretty much explains the situation over at SNGX:



https://ih.advfn.com/p.php?pid=nmona&article=76952221&symbol=SNGX

Financial Results – Year Ended December 31, 2017

Soligenix's revenues for the year ended December 31, 2017 were $5.4 million as compared to $10.4 million for the prior year. Revenues included contracts in support of OrbeShield® (oral beclomethasone 17,21-dipropionate) development for the treatment of gastrointestinal acute radiation syndrome and RiVax®, in addition to the grants received to support the development of SGX301 for the treatment of CTCL and SGX942 for the treatment of oral mucositis in head and neck cancer.

Soligenix's basic net loss was $7.1 million, or ($1.16) per share, as compared to $3.2 million for the prior year, or ($0.93) per share, on a split adjusted basis. Included in the net loss for the year ended December 31, 2016 is non-cash income of $1.5 million. This non-cash item reflects the change in fair value of the liability related to warrants issued in the Company's June 25, 2013 registered public offering and was included in total other income of $1.9 million.